Page 135

Marzo 2016

casos cl ínicos 405 Leukemia Research 2001; 25: 553-62. 9. Theoharides T, Bouchera W, Spear K. Serum Interleukin 6 Reflects Disease Severity and Osteoporosis in Mastocytosis Patients. Int Arch Allergy Immunol 2002; 128: 344-50. 10. Guillaume N, Desoutter J, Chandesris O, Merlusca L, Henry I, Georgin-Lavialle S, et al. Bone complications of mastocytosis: a link between clinical and biological characteristics. Am J Med 2013; 126 (1): 75. e1-7. 11. Brumsen C, Papapoulos SE, Lentjes EGWM, Kluin PM, Hamdy NAT. Potential Role for the Mast Cell in the Pathogenesis of Idiopathic Osteoporosis in Men. Bone 2002; 31 (5): 556-61. 12. Arock M, Valent P. Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives. Expert Rev Hematol 2010; 3 (4): 497-516. 13. Pardanani A, Tefferi A. Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature. Curr Opin Hematol 2010; 17 (2): 125-32. 14. Brumsen C, Hamdy NA, Papapoulos SE. Osteoporosis and bone marrow mastocytosis: dissociation of skeletal responses and mast cell activity during long term bisphosphonate therapy. J Bone Miner Res 2002; 17 (4): 567-9. 15. Marshall A, Kavanagh RT, Crisp AJ. The effect of pamidronate on lumbar spine bone density and pain in osteoporosis secondary to systemic mastocytosis. Br J Rheumatol 1997; 36 (3): 393-6. Compromiso óseo en mastocitosis sistémica - P. Florenzano et al Rev Med Chile 2016; 144: 401-405


Marzo 2016
To see the actual publication please follow the link above